aTyr Pharma (LIFE) Upgraded to “Buy” at Zacks Investment Research

Zacks Investment Research upgraded shares of aTyr Pharma (NASDAQ:LIFE) from a hold rating to a buy rating in a research report report published on Friday. The firm currently has $3.25 price target on the biotechnology company’s stock.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

How to Become a New Pot Stock Millionaire

A number of other research analysts have also commented on LIFE. JPMorgan Chase & Co. lowered aTyr Pharma from a neutral rating to an underweight rating in a research report on Wednesday, February 14th. ValuEngine lowered aTyr Pharma from a sell rating to a strong sell rating in a research report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of $4.75.

Shares of aTyr Pharma (LIFE) remained flat at $$2.95 during mid-day trading on Friday. 15,204 shares of the stock were exchanged, compared to its average volume of 58,024. The company has a market capitalization of $87.90, a PE ratio of -1.56 and a beta of 3.54. aTyr Pharma has a 12 month low of $2.30 and a 12 month high of $6.50. The company has a current ratio of 8.37, a quick ratio of 9.49 and a debt-to-equity ratio of 0.23.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its position in aTyr Pharma by 44.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 25,676 shares during the last quarter. Deutsche Bank AG bought a new position in shares of aTyr Pharma in the 4th quarter worth approximately $199,000. Victory Capital Management Inc. bought a new position in shares of aTyr Pharma in the 3rd quarter worth approximately $455,000. Renaissance Technologies LLC raised its position in shares of aTyr Pharma by 143.2% in the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after acquiring an additional 164,500 shares in the last quarter. Finally, Artal Group S.A. raised its position in shares of aTyr Pharma by 100.0% in the 4th quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after acquiring an additional 250,000 shares in the last quarter. 58.65% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “aTyr Pharma (LIFE) Upgraded to “Buy” at Zacks Investment Research” was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3296288/atyr-pharma-life-upgraded-to-buy-at-zacks-investment-research.html.

About aTyr Pharma

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Callaway Golf  Stock Rating Lowered by DA Davidson
Callaway Golf Stock Rating Lowered by DA Davidson
Zacks Investment Research Upgrades Kindred Healthcare  to “Buy”
Zacks Investment Research Upgrades Kindred Healthcare to “Buy”
ATN International  Upgraded by BidaskClub to Buy
ATN International Upgraded by BidaskClub to Buy
Ladder Capital  PT Set at $16.00 by B. Riley
Ladder Capital PT Set at $16.00 by B. Riley
Debenhams  Price Target Lowered to GBX 20 at Citigroup
Debenhams Price Target Lowered to GBX 20 at Citigroup
Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Cavco Industries  Stock Price
Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Cavco Industries Stock Price


© 2006-2018 Ticker Report. Google+.